



BELLUS Health Reports Second Quarter 2021 Financial Results and Business Highlights

August 11, 2021

- The Phase 2b SOOTHE and Phase 2a BLUEPRINT clinical trials are on track, with topline results expected in Q4 2021 -

LAVAL, Quebec--(BUSINESS WIRE)--Aug. 11, 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the second quarter ending June 30, 2021.

"Our focus remains on the completion of our two ongoing Phase 2 clinical trials – SOOTHE and BLUEPRINT – evaluating our selective P2X3 antagonist BLU-5937, in refractory chronic cough and chronic pruritus associated with atopic dermatitis, respectively. Both clinical trials are advancing on track, with topline results expected in the fourth quarter of 2021," commented Roberto Bellini, President and Chief Executive Officer of BELLUS Health. "We expect the second half of this year to be an exciting time for BELLUS, as we believe the upcoming milestones will be key to advancing the development of BLU-5937."

PROGRAM AND CORPORATE HIGHLIGHTS

Ongoing Phase 2b SOOTHE clinical trial of BLU-5937 in patients with refractory chronic cough ("RCC").

- As of August 2021, the SOOTHE trial has achieved approximately 80% of its enrollment target of 300 patients.
- A pre-specified, blinded Sample Size Re-Estimation ("SSRE") analysis has been conducted, and no changes have been made to the SOOTHE trial size.
- We expect topline results in the fourth quarter of 2021.
- We expect to conduct an administrative interim analysis in September 2021.

Ongoing Phase 2a BLUEPRINT clinical trial of BLU-5937 in patients with chronic pruritus associated with atopic dermatitis ("AD").

- As of August 2021, the BLUEPRINT trial has achieved approximately 90% of its enrollment target of 128 patients.
- A pre-specified, blinded SSRE analysis has been conducted, and no changes have been made to the BLUEPRINT trial size.
- We expect topline results in the fourth quarter of 2021.

Presented clinical data at the American Thoracic Society 2021 International Conference ("ATS").

- Three abstracts on BLU-5937 – including a mini symposium presentation – were presented at ATS, which was held on May 14-19, 2021.

Presenting at the upcoming European Respiratory Society International Congress 2021 ("ERS").

- An abstract on BLU-5937 has been accepted for oral presentation at ERS, which is being held September 5-8, 2021. The pre-recorded presentation will be available on the ERS congress platform on August 23, 2021, with a live QA session on Sunday, September 5, 2021 at 8:45 a.m. EDT.

Ended the second quarter of 2021 with cash, cash equivalents and short-term investments totaling US\$72.3 million.

- We expect current cash position to be sufficient to fund our operating plan until the end of 2022.

FINANCIAL RESULTS

Cash Position: As of June 30, 2021, the Company had available cash, cash equivalents and short-term investments totaling US\$72.3 million, compared to US\$98.3 million on December 31, 2020. The net decrease is primarily attributable to funds used to finance the Company's operating activities, mainly the research and development activities associated with its product candidate BLU-5937.

Net Loss: For the quarter ended June 30, 2021, net loss amounted to US\$17.8 million (US\$0.23 per share), compared to US\$8.4 million (US\$0.14 per share) for the same period in 2020.

Research and Development Expenses: Research and development expenses, net of research tax credits, amounted to US\$15.2 million for the quarter ended June 30, 2021, compared to US\$5.9 million for the same period in 2020, an increase of US\$9.3 million or 158% year over year. The increase is primarily attributable to higher expenses incurred for the development of BLU-5937, mainly activities in relation to the Phase 2b SOOTHE trial in RCC and the Phase 2a BLUEPRINT trial in chronic pruritus associated with AD.

General and Administrative ("G&A") Expenses: General and administrative expenses amounted to US\$2.8 million for the quarter ended June 30, 2021, compared to US\$3.4 million for the same period in 2020, a decrease of US\$0.6 million or 18% year over year. The decrease is mainly due to lower external G&A expenses.

Net Finance Income: Net finance income amounted to US\$0.2 million for the quarter ended June 30, 2021, compared to US\$0.9 million for the same period in 2020.

SUMMARY OF FINANCIAL RESULTS

	Three months ended June 30, 2021		Three months ended June 30, 2020	
	(in thousands of dollars, except per share data)			
Revenues	US\$	4	US\$	6
Research and development expenses, net		(15,201)		(5,899)
General and administrative expenses		(2,805)		(3,439)
Net finance income		174		912
Net loss for the period	US\$	(17,828)	US\$	(8,422)
Basic and diluted loss per share	US\$	(0.23)	US\$	(0.14)

The Company's full unaudited condensed consolidated interim financial statements and accompanying management's discussion and analysis for the three and six-month periods ended June 30, 2021 will be available shortly on SEDAR at www.sedar.com and on EDGAR at www.sec.gov/edgar.

About BLU-5937

BLU-5937, a highly selective P2X3 antagonist - is in development for RCC, chronic pruritus and other hypersensitization-related disorders.

The P2X3 receptor, which is implicated in cough reflex hypersensitization, is a rational target for treating chronic cough, and it has been evaluated in multiple clinical trials with different P2X3 antagonists. The Company believes that its highly selective P2X3 antagonist has the potential to reduce cough frequency in patients with RCC, while limiting taste disturbance adverse events.

In addition to RCC and chronic pruritus, the mechanism of BLU-5937 may also have broad therapeutic applicability across other afferent hypersensitization-related disorders, enabling the Company to consider BLU-5937 as a potential treatment for a number of other indications. Consequently, BELLUS Health is exploring how the P2X3 pathway may contribute to irritation and pain in a variety of afferent hypersensitization-related disorders and whether inhibition of P2X3 receptors can help treat these conditions.

About BELLUS Health (www.bellushealth.com)

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RCC and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of RCC and chronic pruritus associated with AD.

RCC is a cough lasting more than 8 weeks despite appropriate treatment for underlying condition(s). It is estimated that there are approximately 9 million patients in the United States suffering from RCC. RCC is associated with significant adverse physical, social, and psychosocial effects on health and quality of life. Currently, there is no specific therapy approved for RCC and treatment options are limited.

Chronic pruritus associated with AD is an irritating sensation that leads to scratching and persists for longer than 6 weeks in AD patients. It is estimated that up to 10% of adults in the United States suffer from AD – almost all report symptoms of pruritus with over 50% of patients attributing chronic pruritus as their most burdensome symptom. Despite currently available treatments targeting AD, there continues to be a lack of options specifically targeting the burden of pruritus in patients with AD.

Forward-Looking Statements

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute "forward-looking statements" within the meaning of Canadian securities legislation and regulations, the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects," "anticipates," "believes," "intends," "estimates," "potential," "possible," "projects," "plans," and similar expressions. Such statements, based as they are on the current expectations of management, inherently involve numerous important risks, uncertainties and assumptions, known and unknown, many of which are beyond BELLUS Health's control. Such statements include, but are not limited to, the potential of BLU-5937 to successfully treat chronic cough, chronic pruritus and other hypersensitization-related disorders, BELLUS Health's expectations related to its preclinical studies and clinical trials, including the design and timing of its Phase 2b clinical trial of BLU-5937 in RCC and its Phase 2a clinical trial of BLU-5937 in chronic pruritus associated with AD, including the timing and outcome of interactions with regulatory agencies, the potential activity and tolerability profile, selectivity, potency and other characteristics of BLU-5937, including as compared to other competitor candidates, the commercial potential of BLU-5937, including with respect to patient population, pricing and labeling, BELLUS Health's financial position, and the potential applicability of BLU-5937 and BELLUS Health's P2X3 platform to treat other disorders. Risk factors that may affect BELLUS Health's future results include but are not limited to: the benefits and impact on label of its enrichment strategy, estimates and projections regarding the size and opportunity of the addressable RCC market for BLU-5937, the ability to expand and develop its project pipeline, the ability to obtain adequate financing, the ability of BELLUS Health to maintain its rights to intellectual property and obtain adequate protection of future products through such intellectual property, the impact of general economic conditions, general conditions in the pharmaceutical industry, the impact of the COVID-19 pandemic on BELLUS Health's operations, plans and prospects, including to the initiation and completion of clinical trials in a timely manner or at all, changes in the regulatory environment in the jurisdictions in which BELLUS Health does business, stock market volatility, fluctuations in costs, changes to the competitive environment due to consolidation, achievement of forecasted burn rate, potential payments/outcomes in relation to indemnity agreements and contingent value rights, achievement of forecasted preclinical study and clinical trial milestones, reliance on third parties to conduct preclinical studies and clinical trials for BLU-5937 and that actual results may vary once the final and quality-controlled verification of data and analyses has been completed. In addition, the length of BELLUS Health's product candidate's development process and its market size and commercial value are dependent upon a number of factors. Moreover, BELLUS Health's growth and future prospects are mainly dependent on the successful development, patient tolerability, regulatory approval, commercialization and market acceptance of its product candidate BLU-5937 and other products. Consequently, actual future results and events may differ materially from the anticipated results and events expressed in the forward-looking statements. BELLUS Health believes that expectations represented by forward-looking statements are reasonable, yet there can be no assurance that

such expectations will prove to be correct. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These forward-looking statements speak only as of the date made, and BELLUS Health is under no obligation and disavows any intention to update publicly or revise such statements as a result of any new information, future event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see BELLUS Health's public filings with the Canadian securities regulatory authorities, including, but not limited to, its Annual Information Form, and the United States Securities and Exchange Commission, including, but not limited to, its Annual Report on Form 40-F, for further risk factors that might affect BELLUS Health and its business.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210811005775/en/): <https://www.businesswire.com/news/home/20210811005775/en/>

Ramzi Benamar
Chief Financial Officer
rbenamar@bellushealth.com

Media:

Julia Deutsch
Solebury Trout
jdeutsch@soleburytrout.com

Source: BELLUS Health Inc.